Life Sciences Archives - Propel(x)

About Us
Portfolio
How it works
Insights
Sign In
Join

About Us
▼
Portfolio
How it works
▼
Insights
▼
Sign In
Join

Browse articles by categories

Angel Investing Tips

Deep Technology

Startup Tips

User Tips

Industry Trends

Aerospace / Transportation

Energy / Green Technologies

Food & Agriculture

IT & Communications

Life Sciences

Deal Profile

Search for:

Farewell to a very Dickensian 2020 – Founder’s Letter

Swati Chaturvedi December 21st, 2020

Deep Technology Energy / Green Technologies Healthcare Industry Trends Life Sciences

gene therapy

Gene Therapy: Sensational Outcomes. 6-figure Costs.

Luke Renner June 6th, 2018

Deep Technology Industry Trends Life Sciences

Cellular Proximity

Cellular Proximity: Why an Unsolicited Review to Science Magazine may hold the key to the next wave of treatments.

Luke Renner March 28th, 2018

Biology Healthcare Life Sciences

A doctor uses telemedecine to remotely treat his patient. Source: Athenahealth

Deep Tech Innovations in Diagnostics and Medical Technology Are Starting to Transform Healthcare

Luke Renner March 8th, 2018

Deep Technology Industry Trends IT & Communications Life Sciences

biopharma research devices

Biopharma Investment tips from an Industry Expert

Guest Contributor October 19th, 2017

Angel Investing Tips Deep Technology Guest Post Life Sciences

G-Tech non invasive device

G-Tech is developing an IoT GI device that could help millions of Americans each year

Sabrina Canepa October 4th, 2017

Deep Technology IT & Communications Life Sciences

IOT sensors

C2Sense Is Bringing A Sense of Smell to the Digital Age with their Real-Time IoT Sensors

Sabrina Canepa September 29th, 2017

Deep Technology Food & Agriculture Life Sciences Uncategorized

Med tech startup gel-e

Med Tech Startup Gel-E has Developed Revolutionary Technology That Can Almost Instantaneously Stop Bleeding, Even For Severe Wounds

Sabrina Canepa September 11th, 2017

Deal Profile Deep Technology Industry Trends Life Sciences

Pharmaceutical industry

Keeping the Patient in Mind: An Interview with Roz Potter

Jorine Zandhuis June 14th, 2017

Industry Trends Life Sciences Startup Tips

1
2

Popular posts

Guest Post: Cancer Immunotherapy – Defense Against Enemies Foreign and Domestic
Deep Technology
How To Become an Angel Investor
Angel Investing Tips Angel Keyterms User Tips
Deep Tech Innovations in Diagnostics and Medical Technology Are Starting to Transform Healthcare
Deep Technology Industry Trends IT & Communications Life Sciences

ABOUT US
How it works
JOIN
Learn
LEGAL

© 2021 PROPEL(X) - All Rights Reserved.

This site is operated by Propel(x) Inc. (“Propel(x)”), which is not a registered broker dealer. Propel(x) does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities posted here are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. Propel(x) has not taken steps to verify the adequacy, accuracy, or completeness of the information. Neither Propel(x) nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

Certain offerings posted on the platform and so designated are offered by Hubble Investments, Member FINRA / SIPC and an affiliate of Propel(x), located at EvoNexus Silicon Valley FinTech Incubator, 950 Park Place, Building 950/1, San Mateo CA 94403. Hubble Investments does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform. This website is intended solely for qualified investors. Private investments are highly illiquid and risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio. Furthermore, the allocation to this asset sub-class may be best fulfilled through a balanced portfolio of different start-ups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.